Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III crossover equivalence study of dorzolamide 2% eye drops in open angle glaucoma or ocular hypertension
2009-009182-34Phase 3Completed
- Sponsor
- Tiefenbacher
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dorzolamide in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Tiefenbacher. Primary endpoints: Change in mean diurnal intraocular pressure (IOP) from baseline to post-treatment in each period and Safety and tolerability of dorzolamide 2% eye drops. Started Feb 2009; status: completed.
02
Drugs
dorzolamide
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2009-009182-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009182-34.